The document summarizes the validation of transiently transfected cell lines called Ion Channel EZCellsTM TT developed by ChanTest Corp. for high throughput drug screening. The validation showed the cell lines have consistent fluorescent signals in response to potassium stimulation and stable assay performance over multiple experiments. A market analysis estimated the addressable market at $4.5 million and that ChanTest could gain a 17% market share by 2011. The transient transfection approach reduces assay development time and provides a commercially feasible alternative to stable cell lines.